Flexion Therapeutics Inc. (FLXN) announced Thursday morning that it has received positive feedback from the FDA regarding its new drug application for Zilretta. Based on the feedback, the in-person pre-NDA meeting has become unnecessary.
from RTT - Before the Bell http://ift.tt/1qOblEy
via IFTTT
No comments:
Post a Comment